ABSTRACT
Background The WHO 2030 roadmap for schistosomiasis calls for development of highly sensitive and specific diagnostic tools to continue and sustain progress towards elimination. Serological assays are excellent for sensitive detection of primary schistosome infections and for schistosomiasis surveillance in near- and post-elimination settings. To develop accurate assay formats, it is necessary to identify defined antibody targets with low cross-reactivity and potential for standardized production. Here we focus on defined schistosome glycan antigens.
Methods Target identification was performed by assessing antibody responses in well characterized cross-sectional and cohort sample sets (n=366 individuals) on tailor-made antigen microarrays. IgM and IgG binding to candidate diagnostic targets was measured for serum/plasma samples from: controlled human schistosome infection model (CSI), schistosome infected travellers, soil-transmitted helminth infected and non-infected individuals.
Findings We found that antibodies to circulating anodic antigen (CAA) identify schistosome infection with high sensitivity (IgM≥100%, IgG≥97%) and specificity (IgM≥93%, IgG≥97%) in the test samples. Infection dose affected timing of anti-CAA antibody isotype switch. Furthermore, we demonstrate the presence of shared and non-specific glycan epitopes in crude schistosome cercarial and egg antigen preparations. Many non-specific glycan epitopes contained in crude antigen mixes are responsible for a large proportion of false schistosomiasis positives in standard serological assays.
Interpretation CAA is target for development of highly sensitive and specific tools for schistosomiasis serology with use cases for travellers and surveillance in near and post-elimination settings as well as emerging transmission zones.
Funding Global Health Innovative Technology Fund (GHIT), HIC-Vac, Leiden University Medical Center (LUMC)
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Global Health Innovative Technology Fund (GHIT, RFP-TRP-2017-002), Leiden University Medical Center 2020 MSCA-IF Seal-of-Excellence programme, and the Human Infection Challenge Network for Vaccine Development (HIC-Vac, P68501, funded by the GCRF Networks in Vaccines Research and Development which was co-funded by the MRC and BBSRC. This UK funded award is part of the EDCTP2 programme supported by the European Union).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All samples were fully anonymised (also to research group) and with consent for further serological work. CSI:The trial is registered at clinicaltrials.gov with identifier: NCT02755324 and ethical approval given by LUMC Institutional Medical Ethical Research Committee (Institutional Review Board P16.111). PTSP: The study protocol was approved by the Medical Ethics Committee at LUMC Spanish travellers: Hospital Clinic of Barcelona Institutional Review Board and Ethics Committee (HCB/2017/0612). Belgian travellers: Institutional Review Board of Institute of Tropical Medicine (ITM), Antwerpen Indonesian samples: Ethical Committee of the Medical Faculty, University of Indonesia (ethical clearance ref: 194/PT02.FK/Etik/2006) and filed by the Committee of Medical Ethics of the Leiden University Medical Center. The trial was registered as clinical trial (Ref: ISRCTN83830814).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* amok{at}sund.ku.dk
Data Availability
All data in the present study will be made available online upon publication of the work in a peer-reviewed journal.
